Firibastat
Resistant Hypertension
Key Facts
About Quantum Genomics
Quantum Genomics was founded in 2007 with a mission to develop first-in-class, centrally-acting antihypertensives based on inhibition of brain aminopeptidase A (APA). Its primary achievement was advancing its lead candidate, firibastat, into Phase IIb/III clinical trials for resistant hypertension and Phase II for heart failure. The company's strategy was to address significant unmet needs in cardiovascular diseases through a novel mechanism of action complementary to existing therapies. However, the company appears to be in a state of crisis, with its public communications halted and its website displaying a message indicating severe financial insolvency.
View full company profileAbout Quantum Genomics
Quantum Genomics was founded in 2007 with a mission to develop first-in-class, centrally-acting antihypertensives based on inhibition of brain aminopeptidase A (APA). Its primary achievement was advancing its lead candidate, firibastat, into Phase IIb/III clinical trials for resistant hypertension and Phase II for heart failure. The company's strategy was to address significant unmet needs in cardiovascular diseases through a novel mechanism of action complementary to existing therapies. However, the company appears to be in a state of crisis, with its public communications halted and its website displaying a message indicating severe financial insolvency.
View full company profileTherapeutic Areas
Other Resistant Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | CE Mark |
| DirectAblate Renal Denervation System | Symple Surgical | Pre-clinical |
| Aprocitentan | Johnson & Johnson | Approved |
| Baxdrostat | AstraZeneca | Phase III |
| TRYVIO/JERAYGO (aprocitentan) | Idorsia | Marketed |